Artesunate as a Potent Antiviral Agent in a Patient with Late Drug‐Resistant Cytomegalovirus Infection after Hematopoietic Stem Cell Transplantation
Clinical Infectious Diseases2008Vol. 46(9), pp. 1455–1457
Citations Over TimeTop 10% of 2008 papers
Michael Y. Shapira, Igor Resnick, Sunwen Chou, Avidan U. Neumann, Nell S. Lurain, Thomas Stamminger, Orit Caplan, Niveen Saleh, Thomas Efferth, Manfred Marschall, Dana G. Wolf
Abstract
This is the first report of treatment of cytomegalovirus infection with artesunate, for a stem cell transplant recipient with a newly identified foscarnet-resistant and ganciclovir-resistant DNA polymerase L776M mutation. Artesunate treatment resulted in a 1.7-2.1-log reduction in viral load by treatment day 7, with a viral half-life of 0.9-1.9 days, indicating a highly effective block in viral replication.
Related Papers
- → Comparison of intravitreal ganciclovir monotherapy and combination with foscarnet as initial therapy for cytomegalovirus retinitis(2018)12 cited
- → Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro(1990)126 cited
- → Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo(1989)73 cited
- Controversies in the treatment of cytomegalovirus retinitis: foscarnet versus ganciclovir.(1995)
- [In vitro susceptibility to ganciclovir and foscarnet of cytomegaloviruses].(2001)